Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Angiogenesis Année : 2020

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Antoine Vasseur
  • Fonction : Auteur
Olivier Trédan
Anthony Gonçalves
Christelle Lévy
Alexia Savignoni
  • Fonction : Auteur
  • PersonId : 901118
Jean-Yves Pierga

Résumé

Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757).
Fichier non déposé

Dates et versions

hal-02888436 , version 1 (03-07-2020)

Identifiants

Citer

Antoine Vasseur, Luc Cabel, Olivier Trédan, Marion Chevrier, Coraline Dubot, et al.. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). Angiogenesis, 2020, 23 (2), pp.193-202. ⟨10.1007/s10456-019-09697-7⟩. ⟨hal-02888436⟩
127 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More